Professor Christos Reppas, National and Kapodistrian University of Athens, presented an overview of PEARRL research and training activities at the recent European Drug Absorption Network (EDAN) meeting in Leuven March 11-13, 2018.  Professor Reppas’s PEARRL presentation was during one of the dedicated sessions at the EDAN meeting, focusing on EU funded programs in which EDAN participants are involved in including www.orbitoproject.eu  and www.UNGAP.eu). This therefore presented a great opportunity for dissemination of PEARRL activities to a wider scientific audience and also enhancing opportunities for further collaborations with other EU networks. 

Professor Reppas presenting PEARRL

An open symposium on ‘Regulatory Support of Innovation in the Pharmaceutical Industry' on 21st June 2017 as part of the first Annual PEARRLS of Wisdom Week in Cork, Ireland http://www.pearrl.eu/rss2017.html.  PEARRL is a European Training Network (ETN) that brings together partners from European pharmaceutical industry, academia and regulatory agencies as a multi-sectorial team to deliver collaborative research and training network focused on accelerating the development and approval of breakthrough therapy drugs.

The first Annual PEARRLS of Wisdom Week in Cork, Ireland kicked off with a Symposium on Bioenabling Formulations for Oral Drug Delivery, featuring lectures from Consortium Members as well as guest speakers.

The first annual PEARRLs of Wisdom Week at the School of Pharmacy at UCC in Cork, Ireland, are just around the corner and preparations are in full swing. About 70 participants are expected for this 5-day event (19–23 June 2017) with 40 sessions dedicated to developing innovative drug formulation strategies and regulatory tools designed to expedite the development of emerging drug molecules into new licensed medicines.

The PEARRL EU Network is delighted to announce a Regulatory Science Symposium will be held on Wednesday 21st June 2017 at the School of Pharmacy, UCC, CORK.

The PEARRL project officially started on May 1st and will be running for the next three years. The objectives of the PEARRL research programme are to deliver novel bio-enabling formulations and new biopharmaceutics tools to predict their in vivo performance as a means to improve efficiency and cost-competitiveness in drug development, thus facilitating earlier access of patients to “breakthrough therapies”.